What is the clinical relevance of FLT3 and IDH2 mutations in AML?

Sandy Kurtin, PhDc, ANP-C, AOCN

Sandy Kurtin, PhDc, ANP-C, AOCN, on treating patients with AML.


Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here